Central Hospital Of Bolzano
- Address
- lock Available on a paid plan
Musculoskeletal Diseases at Central Hospital Of Bolzano
Clinical research in this area focuses on polymyalgia rheumatica, a painful inflammatory condition that affects the shoulders and hips. The studies are designed to assess whether new treatment approaches can improve symptom control and support more durable remission for people whose disease has recently returned.
- Evaluating a new therapy strategy for polymyalgia rheumatica
- Comparing treatment effectiveness in patients with recent relapse
- Assessing sustained remission as a key outcome of care
This work reflects the Ambulatorio Reumatologico’s interest in improving care for inflammatory rheumatic disease through better long-term disease control.
Neoplasms research in Bolzano
The oncology studies at this site center on high risk non-muscle invasive bladder cancer, with attention to whether adding a new immunotherapy approach can strengthen the effect of standard bladder-directed treatment. The goal is to improve cancer control and reduce the chance that the disease returns or progresses.
- Testing an immunotherapy-based approach for bladder cancer
- Comparing cancer response and disease control strategies
- Studying outcomes that may help prevent recurrence or progression
This research supports efforts to refine treatment for challenging early-stage bladder cancer using combinations of established and newer therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 58 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Janssen Cilag International3active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Central Hospital Of Bolzano
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Nov 2018 | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisone | 5 | Unknown | 2017-06-09 | 2023-09-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.